Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson Sells 9,567 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amal M. Johnson sold 9,567 shares of Intuitive Surgical stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $300.00, for a total transaction of $2,870,100.00. Following the completion of the sale, the director now owns 11,706 shares of the company’s stock, valued at approximately $3,511,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Intuitive Surgical Trading Up 0.8 %

ISRG traded up $2.47 during trading on Friday, reaching $306.42. 2,216,025 shares of the company’s stock were exchanged, compared to its average volume of 1,768,631. Intuitive Surgical, Inc. has a one year low of $222.65 and a one year high of $358.07. The stock has a market capitalization of $107.88 billion, a PE ratio of 72.29, a price-to-earnings-growth ratio of 4.85 and a beta of 1.31. The firm has a fifty day moving average price of $284.12 and a two-hundred day moving average price of $305.07.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 19th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.06. Intuitive Surgical had a net margin of 22.14% and a return on equity of 12.91%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.77 billion. During the same period in the previous year, the firm posted $0.90 EPS. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. Sell-side analysts expect that Intuitive Surgical, Inc. will post 4.54 earnings per share for the current year.

Institutional Investors Weigh In On Intuitive Surgical

A number of institutional investors have recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Intuitive Surgical by 99,583.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 643,694,311 shares of the medical equipment provider’s stock valued at $220,104,833,000 after purchasing an additional 643,048,572 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Intuitive Surgical by 1.7% in the 1st quarter. BlackRock Inc. now owns 28,918,406 shares of the medical equipment provider’s stock valued at $7,387,785,000 after purchasing an additional 470,624 shares during the last quarter. State Street Corp boosted its stake in shares of Intuitive Surgical by 1.9% in the 2nd quarter. State Street Corp now owns 14,810,625 shares of the medical equipment provider’s stock valued at $5,064,345,000 after purchasing an additional 274,201 shares during the last quarter. Capital World Investors boosted its stake in shares of Intuitive Surgical by 0.5% in the 2nd quarter. Capital World Investors now owns 7,510,586 shares of the medical equipment provider’s stock valued at $2,568,118,000 after purchasing an additional 39,671 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Intuitive Surgical by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 6,612,636 shares of the medical equipment provider’s stock valued at $2,254,459,000 after purchasing an additional 167,641 shares during the last quarter. 82.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ISRG has been the subject of several analyst reports. Morgan Stanley dropped their target price on shares of Intuitive Surgical from $330.00 to $300.00 and set an “equal weight” rating for the company in a research report on Monday, October 23rd. Piper Sandler dropped their target price on shares of Intuitive Surgical from $385.00 to $325.00 and set an “overweight” rating for the company in a research report on Friday, October 20th. HSBC initiated coverage on shares of Intuitive Surgical in a research report on Friday. They issued a “buy” rating and a $318.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and issued a $355.00 target price on shares of Intuitive Surgical in a research report on Friday, October 20th. Finally, UBS Group dropped their target price on shares of Intuitive Surgical from $385.00 to $314.00 and set a “neutral” rating for the company in a research report on Thursday, October 19th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $341.05.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.